press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

07 june 2021

alphamab oncology presents phase 2 clinical data on kn046 plus paclitaxel/cisplatin for the first-line treatment of escc at asco 2021 with these positive results, we believe kn046 would help address this huge unmet clinical need of escc patients in future.
07 june 2021

alphamab oncology presents phase 2 clinical data on kn046 combined with chemotherapy for the treatment of advanced nsclc at asco 2021 phase iii clinical study of kn046 combined with chemotherapy for the treatment of squamous nsclc is ongoing, and the first interim analysis expected to be available by the end of 2021.
05 june 2021

poster highlighting clinical data of kn046 plus nab-paclitaxel/gemcitabine as first-line treatment for pancreatic cancer is presented at asco 2021 a phase iii clinical study of kn046 in combination with chemotherapy for the first line treatment of pancreatic cancer will be launched this year.
24 may 2021

poster to highlight envasarc pivotal trial of envafolimab (kn035) will be presented at the 2021 asco annual meeting a pivotal trial in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
20 may 2021

alphamab oncology to present multiple clinical research data at the 2021 american society of clinical oncology annual meeting (asco 2021) data from three clinical studies of the pd-l1/ctla-4 bispecific antibody kn046 will be presented in poster session at the asco 2021
29 april 2021

alphamab announced pd-l1/ctla-4 bispecific antibody kn046 will enter new phase ii clinical trial in combination with pfizer’s inlyta ® (axitinib) to evaluate the efficacy and safety of kn046 in combination with inlyta ® (axitinib) for the first-line treatment of non-small cell lung cancer (nsclc)
20 april 2021

alphamab oncology successfully hosted mid-term investigator's meeting about phase iii clinical research of kn046 in combination with chemotherapy for the treatment of non-small cell lung cancer the enreach-lung-01 trial is the first phase iii clinical trial for the bispecific antibody in the world.
13 april 2021

alphamab oncology presented clinical data of kn046 combined with nab-paclitaxel in the treatment of mtnbc at aacr 2021 the results showed that kn046 plus nab-paclitaxel is well tolerated and efficacious, especially in pd-l1-positive mtnbc patients, showing potentially clinically meaningful benefits in progression-free...
31 march 2021

alphamab oncology appoints mr. weihao xu as chief financial officer weihao xu as chief financial officer, responsible for the company's financial and capital market strategy and investor relations.
23 march 2021

alphamab oncology reports full year 2020 financial results and business highlights 2020 is amilestone year for alphamab oncology. the company has been making significant progress with respect to our drug pipeline and business operations.in 2021, the company expects to launch its fir...